The impact of a novel herbal Shirazi Thymus Vulgaris on primary dysmenorrhea in comparison to the classical chemical Ibuprofen
- PMID: 23798928
- PMCID: PMC3685784
The impact of a novel herbal Shirazi Thymus Vulgaris on primary dysmenorrhea in comparison to the classical chemical Ibuprofen
Abstract
Objective: Primary dysmenorrhea is defined as painful cramps during menstruation with no pelvic pathology. Due to the adverse effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are considered as the most common pharmacological treatment for this disorder. The present study was conducted to assess the impact of Shirazi Thymus Vulgaris compared to that of Ibuprofen on primary dysmenorrhea.
Materials and methods: A randomized, single-blind clinical trial was conducted amongst 120 female students ofIlam University of Medical Sciences, aged 18-25 years who suffered from primary dysmenorrhea. The participants were randomly divided into two groups; one received the herbal and the other classical treatments. The herbal group received 5 ml of the Shirazi Thymus Vulgaris medication that commercially called BronchoT.D, orally four times a day. The classic group received Ibuprofen orally three times a day. A visual analogue scale (VAS) was used to record pain severity.
Results: Pain severity was reduced in both herbal and classic groups with no significant differences. Pain duration at the first and second month of treatment was also similar between two groups.
Conclusions: Shirazi Thymus Vulgaris decreased dysmenorrhea symptoms, which might be attributed to its antispasmodic effects. The herbal Shirazi Thymus Vulgaris can be recommended as an effective medication fortreatment of the primary dysmenorrhea disorder.
Keywords: Ibuprofen; ShiraziThymus Vulgaris; primary dysmenorrheal.
Conflict of interest statement
References
-
- EspínLópez L, Carrillo Verdejo E, González Javier F, Ordoñana Martín JR, Gómez-Amor J. Incidence of anovulatory menstrual cycles among dysmenorrheic and non-non-dysmenorrheic [corrected] women: effects on symptomatology and mood. Psicothema. 2010;22:654–8. - PubMed
-
- Morrison BW, Daniels SE, Kotey P, Cantu N, Seidenberg B. Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial. ObstetGynecol. 1999;94:504–8. - PubMed
-
- French L. Dysmenorrhea in adolescents: diagnosis and treatment. Paediatr Drugs. 2008;10:1–7. - PubMed
-
- Lethaby A, Augood C, Duckitt K, Farquhar C. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev. 2007:CD000400. - PubMed
-
- Nahid K, Fariborz M, Ataolah G, Solokian S. The effect of an Iranian herbal drug on primary dysmenorrhea: Aclinical controlled trial. J Midwifery Womens Health. 2009;54:401–4. - PubMed
LinkOut - more resources
Full Text Sources
Medical